Categorynews

Twist Bioscience and LakePharma Form Strategic Collaboration to Provide Antibody Discovery and Development Services

April 4, 2019 Off By BusinessWire

SAN FRANCISCO & SAN CARLOS, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/DNA?src=hash" target="_blank"gt;#DNAlt;/agt;–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic DNA
using its silicon platform, and LakePharma, Inc., the leading US-based
biologics CRDMO, today announced a strategic collaboration to offer
antibody discovery and development solutions to pharmaceutical and
biotechnology customers.

Under the terms of the agreement, LakePharma will have the ability to
offer Twist’s proprietary antibody discovery and optimization platforms
to their existing and future biopharmaceutical customers as part of
their service offerings. One such platform generated is for discovery of
novel therapeutic antibodies against a major class of protein drug
targets known as GPCRs, which traditionally have been difficult for
biologics drug development. GPCRs have been heavily investigated due to
their involvement in multiple disease classes, including inflammation,
cancer, metabolism, respiratory, and pain. In return, customers of Twist
will have access to LakePharma’s integrated discovery and development
services.

“Twist brings a very different approach to antibody discovery and
optimization, as they are to create synthetic DNA libraries quickly and
tailor the outcome to the needs of our clients to ensure successful
antibody discovery efforts. We are very excited to be able to offer the
Twist antibody discovery and optimization platform to our clients.
LakePharma has been relentless in expanding technologies and
capabilities. The addition of the Twist synthetic DNA libraries is the
latest example of our commitment to provide a diverse range of solutions
for biologics discovery and development,” said Hua Tu, Ph.D., CEO and
chairman of LakePharma.

“LakePharma has established its leadership position in the contract
research, development and manufacturing arena for biologics, expanding
its offerings commensurate with its exceptional growth,” said Emily
Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “Through this
collaboration, we increase our visibility significantly within the
biopharma discovery space. We intend to leverage the incredible
strengths of Twist, with our ability to synthesize any library for a
given target, together with LakePharma’s expertise in integrated
discovery, development and early manufacturing to offer a complete
solution from target to clinical candidate.”

Both Twist Biopharma and LakePharma will be presenting at the 15^th
Annual PEGS Boston, The Essential Protein Engineering Summit, to be held
April 8 to April 12, 2019 in Boston, MA. For more information about
where to find Twist, please click here;
for more information about where to find LakePharma, please click here.

About Twist Biopharma Antibody Discovery Solutions: Writing the
Future of Biologics

Twist Biopharma, the biologics discovery division of Twist Bioscience,
offers proprietary antibody discovery and optimization solutions through
partnerships with biotechnology and pharmaceutical companies. Twist
Bioscience has developed a disruptive DNA synthesis platform that
“writes” DNA on a silicon chip. By leveraging its unique technology to
manufacture DNA at scale, Twist is able to construct proprietary and
truly unique antibody libraries precisely designed to match the
sequences that occur in the human body. These “library of libraries”
provide an integral resource for antibody therapeutic discovery and
optimization that can be utilized by pharmaceutical and biotechnology
companies. For more information, visit www.twistbiopharma.com.

About LakePharma

LakePharma is the leading US-based biologics contract research,
development, and manufacturing organization (CRDMO). The company has
developed a range of technologies and capabilities in antibody
discovery, protein engineering, cell line development, process
optimization, and GMP manufacturing. With comprehensive technologies,
integrated platforms, and five facilities located in key biopharma hubs
on both the East and West Coast, LakePharma enables and supports the
discovery and development of the biologics of tomorrow.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology
company that has developed a disruptive DNA synthesis platform to
industrialize the engineering of biology. The core of the platform is a
proprietary technology that pioneers a new method of manufacturing
synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging
its unique technology to manufacture a broad range of synthetic
DNA-based products, including synthetic genes, tools for next-generation
sequencing (NGS) preparation, and antibody libraries for drug discovery
and development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist makes
products for use across many industries including healthcare, industrial
chemicals, agriculture and academic research.

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements
other than statements of historical facts contained herein are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995, including, but
not limited to, the potential of the collaboration agreement between
Twist Bioscience and LakePharma. Such forward-looking statements involve
known and unknown risks, uncertainties, and other important factors that
may cause Twist Bioscience’s actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
risks and uncertainties of the ability to attract new customers and
retain and grow sales from existing customers; risks and uncertainties
of rapidly changing technologies and extensive competition in synthetic
biology could make the products Twist Bioscience is developing obsolete
or non-competitive; uncertainties of the retention of a significant
customer; risks of third party claims alleging infringement of patents
and proprietary rights or seeking to invalidate Twist Bioscience’s
patents or proprietary rights; and the risk that Twist Bioscience’s
proprietary rights may be insufficient to protect its technologies. For
a further description of the risks and uncertainties that could cause
actual results to differ from those expressed in these forward-looking
statements, as well as risks relating to Twist Bioscience’s business in
general, see Twist Bioscience’s risk factors set forth in Twist
Bioscience’s Annual Report on Form 10-K filed with the Securities and
Exchange Commission on December 20, 2018 and Twist Bioscience’s Form
10-Q for the quarter ended December 31, 2018 filed with the Securities
and Exchange Commission on February 11, 2019. Any forward-looking
statements contained in this press release speak only as of the date
hereof, and Twist Bioscience specifically disclaims any obligation to
update any forward-looking statement, whether as a result of new
information, future events or otherwise.